Geode Capital Management LLC Purchases 12,549 Shares of Axsome Therapeutics, Inc. $AXSM

Geode Capital Management LLC lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.3% during the fourth quarter, Holdings Channel reports. The firm owned 1,010,249 shares of the company’s stock after acquiring an additional 12,549 shares during the period. Geode Capital Management LLC’s holdings in Axsome Therapeutics were worth $184,544,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Axsome Therapeutics by 65.4% during the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Axsome Therapeutics by 602.6% during the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after purchasing an additional 235 shares in the last quarter. Optiver Holding B.V. lifted its position in shares of Axsome Therapeutics by 82.3% during the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after purchasing an additional 130 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in shares of Axsome Therapeutics during the third quarter valued at about $38,000. Finally, Advisory Services Network LLC bought a new position in shares of Axsome Therapeutics during the third quarter valued at about $40,000. 81.49% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Robert W. Baird raised their price target on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Piper Sandler reissued an “overweight” rating and set a $258.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Mizuho raised their price target on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $272.00 price target on shares of Axsome Therapeutics in a research report on Monday, May 4th. Finally, Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $251.26.

Axsome Therapeutics Price Performance

AXSM opened at $233.31 on Thursday. The company has a market capitalization of $12.01 billion, a price-to-earnings ratio of -62.55 and a beta of 0.61. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. The firm has a 50-day moving average price of $199.79 and a 200-day moving average price of $177.40. Axsome Therapeutics, Inc. has a twelve month low of $96.09 and a twelve month high of $238.56.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The company’s revenue for the quarter was up 57.4% compared to the same quarter last year. Equities analysts expect that Axsome Therapeutics, Inc. will post -2.14 EPS for the current year.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark Coleman sold 6,000 shares of Axsome Therapeutics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $230.30, for a total value of $1,381,800.00. Following the completion of the transaction, the director owned 35,140 shares in the company, valued at $8,092,742. This trade represents a 14.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark L. Jacobson sold 4,517 shares of Axsome Therapeutics stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the completion of the transaction, the chief operating officer owned 4,517 shares of the company’s stock, valued at $1,029,604.98. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 29,787 shares of company stock worth $6,470,391 over the last quarter. Corporate insiders own 20.60% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.